主持承擔(dān)國(guó)家自然基金項(xiàng)目1項(xiàng),，題為可控活化的Caspase-3/7的非凋亡功能在乳腺腫瘤發(fā)生及發(fā)展過程中的作用,。參與國(guó)家自然基金項(xiàng)目1項(xiàng)，第二承擔(dān)人,，題為腫瘤生長(zhǎng)抑制因子Rb通過控制能量代謝平衡調(diào)節(jié)細(xì)胞轉(zhuǎn)化作用的機(jī)制研究,。
2007年獲得天津市科學(xué)技術(shù)進(jìn)步三等獎(jiǎng)。(項(xiàng)目：肋間臂神經(jīng)解剖生理學(xué)及在乳腺功能外科的應(yīng)用),。具有GCP資格,，能主持臨床試驗(yàn)。已完成天津市高等學(xué)�,？萍及l(fā)展基金計(jì)劃項(xiàng)目,，CysLT1和CysLT2受體與乳腺癌相關(guān)性的研究，并已成果鑒定,。座客北方網(wǎng)健康大講堂《乳腺癌的解讀和防治》,，http://health.enorth.com.cn/system/2009/04/07/003950289.shtml。
發(fā)表論文：
共發(fā)表論文60篇,，其中SCI收錄文章30余篇,。擔(dān)當(dāng)《現(xiàn)代乳腺疾病治療學(xué)》(2007年人民衛(wèi)生出版社)副主譯。培養(yǎng)碩士研究生,，帶教進(jìn)修生和實(shí)習(xí)醫(yī)生,。參與天津醫(yī)科大學(xué)的留學(xué)生教學(xué)工作，承擔(dān)《腫瘤學(xué)》和《康復(fù)學(xué)》授課,。
發(fā)表主要論文:
(1)Xuchen Cao, Yue Yu, Ying Zhao, Xiaohu Sun, Jie Ge, Bin Zhang, Xin Wang. Down-regulation of miR-129-5p via the Twist1-Snail feedback loop stimulates the epithelial-mesenchymal transition and is associated with poor prognosis in breast cancer. Oncotarget. 2015 accepted (通訊作者)
(2)Zhang J, Wang X (co-first author), Cui W, Liu L, Li Z, Ying G, Zhang N and Li B. Visualization of caspase-3-like activity in cells using a genetically encoded fluorescent biosensor activated by protein cleavage. Nat. Commun. 2013;4:2157. DOI: 10.1038/ncomms3157.
(3)Wang Y, Xing P, Cui W, Wang W, Cui Y, Ying G, Wang X, Li B.Acute Endoplasmic Reticulum Stress-Independent Unconventional Splicing of XBP1 mRNA in the Nucleus of Mammalian Cells. Int. J. Mol. Sci. 2015, 16, 13302-13321(通訊作者)
(4)Xiangmin Ma, Yunwei Han, Yu Fan, Xuchen Cao and Xin Wang*. Clinicopathological characteristics and prognosis of glycogen-rich clear cell carcinoma of the breast. The Breast Journal. 2014;20(2):166-173. (通訊作者)
(5)Yunwei Han, Zhihao Yu, Shaoyan Wen, Bin Zhang, Xuchen Cao, Xin Wang. Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. Breast Cancer Res Treat 2012; 131:483–490. (通訊作者)
(6)Liu J, Yu Y, Sun JY, He SS, Wang X, Yin J, Cao XC. Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast. Breast Cancer Res Treat. 2015 Jan;149(1):133-40.
(7)肖盟,趙洪猛,楊正軍,湯小川,曹旭晨,王欣.乳腺化生性癌的臨床病理特征及預(yù)后影響因素.中國(guó)腫瘤臨床2015;42(12):614-619 (通訊作者)
(8)邢芳,，肖盟，穆蘭,，王欣.血糖監(jiān)測(cè)在乳腺癌治療中的臨床意義.中國(guó)腫瘤臨床2015;42(10):513-518 (通訊作者)
(9)穆蘭,邢芳,肖盟,王欣.二甲雙胍與乳腺癌關(guān)系的研究進(jìn)展.中國(guó)腫瘤臨床2014;41(21):1413-1415 (通訊作者)
(10)肖盟,邢芳,穆蘭,王欣.乳管鏡臨床診治新進(jìn)展.中國(guó)腫瘤臨床2014;18:1199-1201. (通訊作者)
(11)馬祥敏,，崔文靜,，張矯，王欣*.乳腺癌原發(fā)腫瘤與局部復(fù)發(fā)腫瘤組織中受體表達(dá)的差異及其臨床意義.中華腫瘤雜志2013;35(5):372-376. (通訊作者)
(12)崔文靜,，張矯,，馬祥敏，王雯雯,，王欣*.含串聯(lián)多拷貝DNA序列的質(zhì)粒載體的構(gòu)建.天津醫(yī)藥,，7:720-721，2013(通訊作者)
(13)崔文靜,，張矯,，馬祥敏，王雯雯,，王欣*.雙啟動(dòng)子shRNA干擾的協(xié)同效應(yīng).山東醫(yī)藥,，2013;53(11):25-28. (通訊作者)
(14)張矯，崔文靜,，馬祥敏,，王雯雯，王欣*. Npu DnaE高效反式剪接作用在哺乳動(dòng)物細(xì)胞中的應(yīng)用研究.山東醫(yī)藥2013;53(44):10-13. (通訊作者)
(15)張矯,，崔文靜,，馬祥敏，王雯雯,，王欣*.熒光蛋白Venus載體構(gòu)建及在哺乳動(dòng)物細(xì)胞中的表達(dá).山東醫(yī)藥，2013;53(31):23-25. (通訊作者)
(16)王欣劉偉韓蕓蔚馮玉梅李代清.半胱氨酰白三烯受體在乳腺癌組織中的表達(dá)及意義.中國(guó)腫瘤臨床2012;20: 1522-1526. (通訊作者)
(17)張矯,，崔文靜,，馬祥敏，李代清,，王欣.糖尿病與乳腺癌相關(guān)性研究進(jìn)展.中華內(nèi)分泌外科雜志,， 2012.5:343-345. (通訊作者)
(18)馬祥敏，崔文靜,，張矯,，王欣.老年人乳腺癌綜合治療研究進(jìn)展.中華老年醫(yī)學(xué)雜志2012;31(5):442-444. (通訊作者)
(19)韓蕓蔚，常新忠,，溫紹艷,，王欣。男性和女性乳腺癌臨床病理特征的配對(duì)比較及生存分析.中華內(nèi)分泌外科雜志2012;6(2):102-105,。(通訊作者)
(20)韓蕓蔚,，王欣，張斌,，溫紹艷,，劉偉,，曹旭晨。新輔助化療誘導(dǎo)的粒細(xì)胞減少癥對(duì)乳腺癌預(yù)后的影響.中華普通外科雜志2011;8(26):651-654. (通訊作者)
(21)溫紹艷,，韓蕓蔚,，馬祥敏，等.三陰性乳腺癌的鉬靶影像學(xué)表現(xiàn)和臨床病理特征[J].中華腫瘤雜志,，2012,，34(4):291-295。(通訊作者)
(22)溫紹艷,，王欣,，曹旭晨.新輔助化療乳腺癌前哨淋巴結(jié)活檢時(shí)機(jī)的選擇問題[J].中國(guó)腫瘤外科雜志，2012,，4(2):108-111(通訊作者)
(23)韓蕓蔚,，溫紹艷，劉偉,，王欣,。乳腺癌新輔助化療的臨床評(píng)價(jià)進(jìn)展.中國(guó)腫瘤臨床2011;38(7):408-411. (通訊作者)
(24)劉偉，李越,，趙穎,，等.乳腺癌腋窩淋巴結(jié)B超檢查特異性回顧性分析.中國(guó)實(shí)用外科雜志2011;31(1):96-99. (通訊作者)
(25)劉偉，韓蕓蔚,，溫紹艷,，等.乳腺中央型及外周型乳頭狀瘤癌變的外科治療中國(guó)腫瘤臨床，2011;38(10):574-577. (通訊作者)
(26)Wang X,，Zhao Y and Cao X. Clincal benefits of mastectomy on treatment of occult breast csrcinoms presenting axillary metastases. The Breast Journal 2010;16:32-37.(通訊作者)
(27)于治灝,，李越，王欣.Angiomotin在乳腺癌中的研究進(jìn)展.中華乳腺病雜志2010;4:53-56.(通訊作者)
(28)李越,王欣,趙穎,葛潔,張斌,于治灝,寧連勝,曹旭晨.超聲光散射乳腺成像診斷乳腺癌假陽性率分析.中國(guó)腫瘤臨床.2010;37:704-6. (通訊作者)
(29)王欣,，李越,，趙穎，葛潔,，張斌,，寧連勝，曹旭晨.光學(xué)功能成像技術(shù)在乳腺癌早期診斷中的應(yīng)用.中華乳腺病雜志2009,3(4):42-45.
(30)李越,，趙穎,，張斌，葛潔,，寧連勝,，曹旭晨，于治灝，王欣.超聲光散射乳腺成像診斷乳腺癌的臨床價(jià)值.中華乳腺病雜志2009,3(4):20-24.(通訊作者)
(31)李越,，王欣,，于治灝，趙穎,，寧連勝,，曹旭晨.乳腺Paget’s病的臨床病理分析.中國(guó)腫瘤臨床2009,36(17):980-982. (通訊作者)
(32)李越，王欣5-FU代謝酶基因型多態(tài)性與乳腺癌化療敏感相關(guān)性研究的進(jìn)展.中華腫瘤防治雜志2009,16(15):1192-1195. (通訊作者)
(33)閆哲,，王欣. Cystatins與腫瘤發(fā)生發(fā)展關(guān)系的研究現(xiàn)狀,。中華乳腺病雜志2008;2(5):47-51.(通訊作者)
(34)王欣，閆哲,，李曉青,，馮玉梅和曹旭晨。Cystatin M在乳腺癌及轉(zhuǎn)移癌中的表達(dá)和臨床意義,。中華乳腺病雜志2008;2(3):21-25.
(35)Wang X and Ning L. Breast carcinoma associated with Poland’s syndrome: One case report and literatures. Chinese Journal of Clinical Oncology 2008;5(3): 223-225.
(36)Wang X, Cao X and Ning L. Traumatic neuromas after mastectomy. ANS J Surg. 2007; 77:1.
(37)王欣,，寧連勝. Poland綜合征合并乳腺癌1例報(bào)道及文獻(xiàn)回顧.中國(guó)腫瘤臨床2008;35(2):78-79.
(38)Wahlbom M, Wang X, Lindström V, Carlemalm E, Jaskolski M and Grubb A. Fibrillogenic oligomers of human cystatin C are formed by propagated domain swapping. J Biol Chem. 2007;282(25):18318-26.
(39)Wang X, Cao X and Ning L. Traumatic Neuromas in breast cancer patients after mastectomy. Chinese J of Clinical Oncology 2007;4(3):185-188.
(40)Wang X. Presentation of Axillary Metastases from Occult Breast Carcinoma. Chinese J of Clinical Oncology 2007;4:1-5.
(41)Selenica M, Wang X, Pedersen LO, Grubb A and Westlind-Danielsson A. Cystatin C Reduces the Formation of Soluble A1-42 Oligomers and Protofibrils. Scand J Clin Lab Invest 2007;67(2):179-90.
(42)Ning L, Wang X, Zhao K, et al. Anatomical study of intercostobrachial never in SD rat. Chinese J of Clinical Oncology 2006;3:118-121.
(43)Rodziewicz-Motowidio, S, Wahlbom M, Wang X, et al. Checking the conformational stability of cystatin C and its L68Q variant by molecular dynamics studies: Why is the L68Q variant amyloidogenic? Journal of Structural Biology 2006;154(1):68-78.
(44)Nilsson M, Wang X, Rodziewicz-Motowidlo S, et al. Prevention of domain swapping inhibits dimerization and amyloid fibril formation of cystatin C - Use of engineered disulfide bridges, antibodies, and carboxymethylpapain to stabilize the monomeric form of cystatin C. JOURNAL OF BIOLOGICAL CHEMISTRY 279 (23): 24236-24245 JUN 4 2004 ［共享第一作者］
(45)Chen D, Zhao CM, Wang X, et al. Target for gene therapy of gastric cancer: Gastrin? Helicobacter pylori infection may result in gastric cancer in hypergastrinemic mice but not in gastrin-deficient mice. CANCER GENE THERAPY 11 (12): 851-851 P6 DEC 2004
(46)Zhao CM, Wang X, Friis-Hansen L, et al. Chronic Helicobacter pylori infection results in gastric hypoacidity and hypergastrinemia in wild-type mice but vagally induced hypersecretion in gastrin-deficient mice. REGULATORY PEPTIDES 115 (3): 161-170 OCT 15 2003.
(47)Liuba P, Pesonen E, Paakkari I, et al. Co-infection with Chlamydia pneumoniae and Helicobacter pylori results in vascular endothelial dysfunction and enhanced VCAM-1 expression in ApoE-knockout mice. JOURNAL OF VASCULAR RESEARCH 40 (2): 115-122 MAR-APR 2003.
(48)Wang X, Willen R, Svensson M, et al. Two-year follow-up of Helicobacter pylori infection in C57BL/6 and Balb/cA mice. APMIS 111 (4): 514-522 APR 2003
(49)Chen D, Zhao CM, Wang X, et al. Disparate effects of chronic Helicobacter pylori infection on parietal cells and ECL cells in wild-type vs gastrin-deficient mice. INTERNATIONAL JOURNAL OF CANCER : 220-220 Suppl. 13 2002
(50)Wang X: Helicobacter pylori infection in a mouse model: Development, optimization and inhibitory effects of antioxidants. Doctoral thesis, 2001, Department of Medical Microbiology, Dermatology and Infection, University of Lund, Lund, Sweden. (http://www.lub.lu.se/luft/diss/med558_transit.html)
(51)Wang X, Hirmo S, Willén R, Wadström T. Inhibition of Helicobacter pylori infection by bovine milk glycoconjugates in a BALB/cA mouse model. J Med Microbiol 2001; 50: 430-435.
(52)Wang X, Willen R, Wadstrom T: Astaxanthin-rich algal meal and vitamin C inhibit Helicobacter pylori infection in BALB/cA mice. Antimicrob Agents Chemother 2000;44(9):2452-7.
(53)Wang X, Willen R, Andersson C, Wadstrom T: Development of high-grade lymphoma in Helicobacter pylori-infected C57BL/6 miceNote. Apmis 2000;108(7-8):503-508.
(54)Wang X, Sjunnesson H, Sturegård E, Wadström T, Willén R and Aleljung P. Dietary factors influence the recovery rates of Helicobacter pylori in a BALB/cA mouse model. B&K Science Now 2000;9:1-6.
(55)Willen R, Carlen B, Wang X, Papadogiannakis N, Odselius R, Wadstrom T: Morphologic conversion of Helicobacter pylori from spiral to coccoid form. Scanning (SEM) and transmission electron microscopy (TEM) suggest viability. Ups J Med Sci 2000;105(1):31-40.
(56)Bennedsen M, Wang X, Willen R, Wadstrom T, Andersen LP: Treatment of H. pylori infected mice with antioxidant astaxanthin reduces gastric inflammation, bacterial load and modulates cytokine release by splenocytes. Immunol Lett 1999;70(3):185-9.
(57)Wang X, Sjunnesson H, Sturegard E, Wadström T, Willén R, Aleljung P: Dietary factors influence the recovery rates of Helicobacter pylori in a BALB/cA mouse model. Zentralbl Bakteriol 1998;288(2):195-205.
(58)Wang X, Willén R, Wadström T, Aleljung P: RAPD-PCR, histopathological and serological analysis of four mouse strains infected with multiple strains of Helicobacter pylori. Microbial Ecology in Health and Disease 1998;10:148-154.
(59)Wang X, Sturegard E, Rupar R, Nilsson HO, Aleljung PA, Carlén B, Willén R, Wadström T: Infection of BALB/c A mice by spiral and coccoid forms of Helicobacter pylori. J Med Microbiol 1997;46(8):657-63.
(60)Aleljung P, Nilsson HO, Wang X, Nyberg P, Morner T, Warsame I, Wadström T: Gastrointestinal colonisation of BALB/cA mice by Helicobacter pylori monitored by heparin magnetic separation. FEMS Immunol Med Microbiol 1996;13(4):303-9.
|
